These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 30373175

  • 21. Bispecific Antibodies for Triple Negative Breast Cancer.
    Dees S, Ganesan R, Singh S, Grewal IS.
    Trends Cancer; 2021 Feb; 7(2):162-173. PubMed ID: 33041246
    [Abstract] [Full Text] [Related]

  • 22. Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, and Angiogenesis Inhibition in Triple-Negative Breast Cancer Cells.
    Ahmed SA, Mendonca P, Messeha SS, Soliman KFA.
    Molecules; 2023 Sep 09; 28(18):. PubMed ID: 37764312
    [Abstract] [Full Text] [Related]

  • 23. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with 177Lu Is More Potent for Killing Human Breast Cancer Cells That Coexpress HER2 and EGFR Than Single-Receptor-Targeted (SRT) Radiation Nanomedicines.
    Yook S, Cai Z, Jeong JJ, Lu Y, Winnik MA, Pignol JP, Reilly RM.
    Mol Pharm; 2020 Apr 06; 17(4):1226-1236. PubMed ID: 32022567
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF, De Martino M, Venturutti L, Rivas MA, Proietti CJ, Inurrigarro G, Frahm I, Allemand DH, Deza EG, Ares S, Gercovich FG, Guzmán P, Roa JC, Elizalde PV, Schillaci R.
    Clin Cancer Res; 2017 Feb 01; 23(3):636-648. PubMed ID: 27698002
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Synthesized Anti-HER2 Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity.
    Shafiee S, Mirzaei R, Salehi M, Jalili N, Taheri A, Farahmand L.
    Iran J Immunol; 2023 Sep 01; 20(3):303-315. PubMed ID: 37434357
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
    Liu Y, Wang Y, Yu S, Zhou Y, Ma X, Su Q, An L, Wang F, Shi A, Zhang J, Chen L.
    Cell Physiol Biochem; 2019 Sep 01; 52(3):382-396. PubMed ID: 30845378
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Calcium signaling affects migration and proliferation differently in individual cancer cells due to nifedipine treatment.
    Chovancova B, Liskova V, Miklikova S, Hudecova S, Babula P, Penesova A, Sevcikova A, Durinikova E, Novakova M, Matuskova M, Krizanova O.
    Biochem Pharmacol; 2020 Jan 01; 171():113695. PubMed ID: 31706846
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
    Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T.
    Cancer Sci; 2016 Jul 01; 107(7):1039-46. PubMed ID: 27166974
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.